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Background
Ritonavir-boosted protease inhibitor (PI/r) monotherapy
has several potential benefits over standard PI-based
combination antiretroviral therapy (cART) and has
recently been included in the European HIV treatment
guidelines. However, there are concerns about its effi-
cacy. We performed a meta-analysis comparing PI/r
monotherapy to cART to examine its efficacy.
Methods
We searched electronic databases (Pubmed, EMBASE,
Central) from 1996 to 2010 using keywords, “protease
inhibitor”, “antiretroviral”, “monotherapy”, relevant drug
names and standard “HIV” and “RCT” search strings on
March 22, 2010, without limits to language. We
searched major HIV-related conferences manually from
2007 and contacted experts. Two reviewers indepen-
dently assessed citations for eligibility and extracted
relevant data. Assessment of bias of individual studies
was performed independently by both reviewers. We did
not include review articles, single-arm trials, or observa-
tional studies.
Results
Of the 137 citations identified, we reviewed 19 articles
after duplicates and obviously unrelated titles were dis-
carded. Of these, 6 met eligibility criteria. Four additional
abstracts were identified from conference abstracts. Ten
RCTs (1265 participants) were included in meta-analysis
using random effects Mantel-Haenszel methods. Summary
estimate for the outcome of viral suppression (<50 copies/
ml) on PI/r monotherapy compared to cART using
intention to treat analysis (ITT), where reinduction and
missing data count as failure, was RRMHRE 0.94 (95% CI
0.89-0.99) without evidence of heterogeneity (p-value 0.55
and I
2 0%). Using on-treatment (OT) analysis, where miss-
ing information, deaths and drug changes due to adverse
events were censored, the summary estimate was RRMHRE
0.90 (95% CI 0.85-0.96, 1113 participants). There was no
evidence of statistical heterogeneity in the OT analysis (p-
value 0.01, I
2 57%). All studies were open-label. There was
variability in study populations (treatment naïve vs experi-
enced) and in interventions (LPV/r vs DRV/r monother-
apy and cART regimens). Excluding the only RCT that
started PI/r monotherapy in patients with unsuppressed
HIV, did not change the ITT summary estimate.
Conclusions
Our meta-analysis of 10 RCTs suggests that PI/r mono-
therapy is slightly but significantly less effective than
cART. Subgroups of patients, however, may benefit
from this promising alternative treatment strategy.
Future RCTs should focus on these patients.
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